- Report
- February 2024
- 70 Pages
Italy
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Oman
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
France
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
United States
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Spain
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Iran
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Russia
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Australia
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
China
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Japan
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4533EUR$4,750USD£3,798GBP

Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes medications.
Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more